SERPINA1 and alpha 1-antitrypsin deficiency: By restoring the expression of functional protein at the RNA level, this approach aims to reduce the accumulation of misfolded protein in the liver and improve systemic levels of functional alpha-1 antitrypsin, addressing both liver and lung disease manifestations of AATD in a targeted, potentially safer manner than traditional gene therapy.